The North America liposome drug delivery market is expected to reach US$ 2735.64 million by 2027 from US$ 1390.53 million in 2019. The market is estimated to grow with a CAGR of 9% from 2020 to 2027.
The liposome drug delivery market is growing primarily due to the Increasing Prevalence of chronic diseases, increasing demand for non-invasive drug delivery system along with rising R&D expenditures by pharmaceutical companies are some of the driving force of the market. Whereas, high cost associated with development of Non-invasive drug delivery system is about to hinder the market growth during forecast period.
The Liposome are novel drug delivery system (NDDS) , they are vesicular structures consisting of bilayers which form spontaneously when phospholipids are disappeared in water. They are microscopic vesicles in which an aqueous volume is entirely enclosed by a membrane composed of lipid bilayers.
Over the past few decades, research and development (R&D) in liposomal drug delivery systems is increasing across the world due to increasing prevalence of chronic disease.Drug delivery is the process of administering a pharmaceutical compound to achieve a therapeutic effect in humans.
Liposomal drug delivery offers various advantages such as improved pharmacokinetics and pharmacodynamics, enhanced therapeutic efficacy, and decreased toxicity making these delivery systems ideal for patients suffering from various chronic conditions. According to the Centers for Disease Control and Prevention (CDC) in the 2019, almost 6 in 10 people in the US suffer from at least one chronic disease and 4 in 10 people have two or more chronic diseases.
Liposomes are rapidly gaining acceptance as nano-carriers for various pharmaceutical applications.Compositions of cholesterol and phospholipids are becoming increasingly useful in liposome drug delivery.
As the nanoscience is optimizing liposome drug delivery, the pharmaceutical and biotechnology companies are exploring alternative compositions with cholesterol as well as new techniques such as nanotechnology to improve the stability and drug release profiles with the help of encapsulation and other techniques. They are using liposomes for the generation of extracellular vesicles by targeted cells.
Manufacturers in the liposome drug delivery market are ramping up their R&D activities in order to unlock new lipid compositions and strategies that help to optimize the drug transport and stability of liposomes.
Research institutes, pharmaceutical, and biotech companies are now focusing in collaborative work to address the COVID-19 outbreak.This has eventually shifted their focus from their regular supply of liposome drug delivery.
Majority of the companies which are operating in the manufacturing segment of liposome drug delivery products are currently working on various therapeutic segment to tackle the pandemic situation.In the upcoming years, the research activities are expected to accelerate owing to their potential in treating wide range of diseases.
The COVID-19 outbreak highlights potential vulnerabilities in both our drug supply chain and clinical infrastructure, including the availability of adequate clinician resources.
Some of the significant secondary sources for automated compounding systems market included in the report are the Food and Drug Administration (FDA), World Health Organization (WHO).
Our reports have been used by over 10K customers, including:
The South and Central America liposome drug delivery market is expected to reach US$ 206.29 million by 2027 from US$ 116.72 million in 2019. The market is estimated to grow with a CAGR of 7.5% from 2020 to 2027. The liposome drug delivery market is growing primarily due to the Increasing Prevalence of chronic diseases, increasing demand...
Market Introduction The Liposome are novel drug delivery system (NDDS), they are vesicular structures consisting of bilayers which form spontaneously when phospholipids are disappeared in water. They are microscopic vesicles in which an aqueous volume is entirely enclosed by a membrane composed of lipid bilayers. Market Overview...
Vaginal Cancer - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Pipeline Review, H2 2020, provides an overview of the Vaginal Cancer (Oncology) pipeline landscape. Vaginal cancer is a rare cancer that occurs in vagina. Symptoms...
Histone Deacetylase 1 - Pipeline Review, H2 2020 Summary Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) pipeline Target constitutes close to 38 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase...
Coronary Stents - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Coronary Stents - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Coronary Stents pipeline products with comparative analysis of the products at various stages...
Medical Foam Market Research Report by Form (Flexible Foam, Rigid Foam, and Spray Foam), by Material (Latex, Metals, and Polymers), by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Medical Foam Market is expected to grow from USD 24,856.97 Million in 2019 to USD 36,574.46 Million by...
The Europe liposome drug delivery market was valued at US$ 1,164.54 million in 2019 and is projected to reach US$ 2,160.12 million by 2027; it is expected to grow at a CAGR of 8.2% during the forecast period. The growing R&D expenditure on drug delivery, growing demand for non-invasive drug delivery devices. and the development of new...
The Asia Pacific liposome drug delivery market is expected to reach US$ 1,562.92 million in 2027 from US$ 759.81 in 2019. The market is estimated to grow with a CAGR of 9.6% from 2020-2027. The growth of the market is attributed to the some key driving factors such as high incidence of chronic diseases amongst the population, an upsurge...
Gallbladder Cancer - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2020, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape. Gallbladder cancer is a cancer that starts in the gallbladder....
Ewing Sarcoma - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Pipeline Review, H2 2020, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape. Ewing’s sarcoma is a primary bone cancer that affects mainly children...
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.